Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis

Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis

Context The use of traditional Chinese medicine (TCM) for breast cancer patients inhibits tumor cell growth and proliferation, alleviates adverse reactions, and inhibits tumor recurrence and metastasis post-surgery. An assessment of its historical efficacy and an examination of the latest research t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun Yuan, Yun Liu, Tiantian Zhang, Cheng Zheng, Xiao Ding, Chuanrong Zhu, Jing Shi, Yi Jing
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Pharmaceutical Biology
Subjects:	Apoptosis expression proliferation chemotherapy triple-negative breast cancer lymphedema
Online Access:	https://www.tandfonline.com/doi/10.1080/13880209.2024.2359105
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
by: Ruiliang Chen, et al.
Published: (2024-12-01)

Factors affecting lymphedema after neoadjuvant chemotherapy and axillary dissection in female breast cancer patients: a retrospective cohort study based on the Chinese population
by: Jianqin Fu, et al.
Published: (2024-10-01)

Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk
by: Xinyu Ren, et al.
Published: (2025-04-01)

Biochemical pathways mediated by KLK6 protease in breast cancer
by: Georgios Pampalakis, et al.
Published: (2019-11-01)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
by: Sarah Talamantes, et al.
Published: (2020-10-01)

Galangin promotes apoptosis by upregulating the pro-apoptotic gene BAX in triple-negative breast cancer
by: Shruti Sinnarkar, et al.
Published: (2024-12-01)

Multifaceted impact of HIV inhibitor dapivirine on triple negative breast cancer cells reveals potential entities as targets for novel therapy
by: Ketki Patil, et al.
Published: (2024-12-01)

Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors
by: Nevena Ilieva, et al.
Published: (2024-11-01)

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy
by: Özgen Arslan Solmaz, et al.
Published: (2025-01-01)

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
by: Huayan Gu, et al.
Published: (2025-02-01)

Inflammatory Breast Cancer and Transient Complete Radiographic Response to Chemoimmunotherapy: A Case Report
by: Adina Amin, et al.
Published: (2024-10-01)

RSL3 induces ferroptosis by activating the NF-κB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel
by: Jialin Yuan, et al.
Published: (2025-01-01)

Telomerase and mitochondria inhibition promote apoptosis and TET2 and ANMT3a expression in triple negative breast cancer cell lines
by: Zeinab Mazloumi, et al.
Published: (2024-07-01)

Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition
by: Danxiang Chen, et al.
Published: (2024-12-01)

Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells
by: Sima Kianpour Rad, et al.
Published: (2025-01-01)

The analysis of gene co-expression network and immune infiltration revealed biomarkers between triple-negative and non-triple negative breast cancer
by: Yao Yi, et al.
Published: (2025-01-01)

Investigation of survival and prognostic factors in triple negative molecular subtype male breast cancer patients: A population-based study
by: Ahmet Necati Sanli, et al.
Published: (2024-04-01)

Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy
by: Tao Ma, et al.
Published: (2025-01-01)

SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer
by: Yu-Chia Chen, et al.
Published: (2024-11-01)

The overview of modern approaches in treatment of triple negative breast cancer
by: A. A. Kharitonova, et al.
Published: (2020-03-01)

Investigation and Analysis of Cognition of Upper Limb Lymphedema in Postoperative Breast Cancer Patients
by: Xuelin YUAN, et al.
Published: (2017-12-01)

Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
by: Jia-xin Qiao, et al.
Published: (2024-12-01)

Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer
by: Chang Cheng, et al.
Published: (2025-01-01)

Mechanistic exploration of Traditional Chinese Medicine regulation on tumor immune microenvironment in the treatment of triple-negative breast cancer: based on CiteSpace and bioinformatics analysis
by: Dandan Feng, et al.
Published: (2025-01-01)

Integrated analysis of hub genes and intrinsically disordered regions in triple-negative breast cancer
by: Azhar Iqbal, et al.
Published: (2024-12-01)

Triple-negative breast cancer patients treated with subcutaneous mastectomy with immediate reconstruction: single institution experience
by: Artur Bocian, et al.
Published: (2024-12-01)

Comprehensive analysis of the metabolomics and transcriptomics uncovers the dysregulated network and potential biomarkers of Triple Negative Breast Cancer
by: Sisi Gong, et al.
Published: (2024-11-01)

Role of Axillary Lymph Nodes Involvement in Some Complications of Modified Radical Mastectomy
by: Hussein Abbas Obaid, et al.
Published: (2024-12-01)

Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6/JAK2/STAT3 pathway
by: Rumeng Ding, et al.
Published: (2025-01-01)

DLAT promotes triple-negative breast cancer progression via YAP1 activation
by: Diya Liu, et al.
Published: (2024-12-01)

Research trends on lymphedema after mastectomy for breast cancer patients from 2000 to 2023: a scientometric analysis
by: Ling Chen, et al.
Published: (2025-02-01)

Chaperonin‐containing TCP1 subunit 6A inhibition via TRIM21‐mediated K48‐linked ubiquitination suppresses triple‐negative breast cancer progression through the AKT signalling pathway
by: Mengdi Yang, et al.
Published: (2024-11-01)

Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study
by: Leonor Vasconcelos de Matos, et al.
Published: (2024-12-01)

Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtype
by: Grace L. Smith, et al.
Published: (2024-12-01)

Cilengitide sensitivity is predicted by overall integrin expression in breast cancer
by: Nomeda Girnius, et al.
Published: (2024-12-01)

Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes
by: Cheng C, et al.
Published: (2025-01-01)

Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer
by: Xu H, et al.
Published: (2024-12-01)

A Case Report of Application of Short-stretch Bandage Treatment in Upper Limb Lymphedema after Breast Cancer Surgery
by: Liuya JIANG, et al.
Published: (2017-12-01)

Investigating the therapeutic effect of folic acid conjugated ZnO nanoparticles on human triple negative breast cancer cell line
by: Shiva Sabzandam, et al.
Published: (2023-06-01)

Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
by: Xing Wang, et al.
Published: (2024-11-01)